Form 4: Kemal Malik Acquires Shares and Stock Options in Cartesian Therapeutics

Director Kemal Malik reports acquisition of common stock and stock options in Cartesian Therapeutics (RNAC) on July 1, 2024.

Summary

• Kemal Malik, a director of Cartesian Therapeutics, Inc. (RNAC), reported acquiring 5,933 shares of common stock and 7,600 stock options on July 1, 2024.
• The common stock was acquired at a price of $0.
• The stock options have an exercise price of $24.27 and expire on June 30, 2034.
• The restricted stock units vest in three equal annual installments, fully vesting on July 1, 2027.
• The stock options vest in 36 equal monthly installments, fully vesting on July 1, 2027.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The acquisition itself could be seen as slightly positive, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies. This filing indicates changes in beneficial ownership by a company director.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates